AGL 40.39 Increased By ▲ 0.38 (0.95%)
AIRLINK 127.50 Decreased By ▼ -0.49 (-0.38%)
BOP 6.60 No Change ▼ 0.00 (0%)
CNERGY 4.51 Decreased By ▼ -0.09 (-1.96%)
DCL 8.56 Increased By ▲ 0.08 (0.94%)
DFML 42.30 Increased By ▲ 0.82 (1.98%)
DGKC 87.25 Increased By ▲ 0.67 (0.77%)
FCCL 32.61 Increased By ▲ 0.47 (1.46%)
FFBL 65.21 Decreased By ▼ -0.21 (-0.32%)
FFL 10.23 Decreased By ▼ -0.02 (-0.2%)
HUBC 109.75 Decreased By ▼ -0.74 (-0.67%)
HUMNL 14.57 Decreased By ▼ -0.18 (-1.22%)
KEL 5.12 Decreased By ▼ -0.01 (-0.19%)
KOSM 7.53 Increased By ▲ 0.41 (5.76%)
MLCF 41.59 Decreased By ▼ -0.06 (-0.14%)
NBP 59.53 Decreased By ▼ -0.56 (-0.93%)
OGDC 194.10 Decreased By ▼ -0.59 (-0.3%)
PAEL 28.17 Increased By ▲ 0.22 (0.79%)
PIBTL 7.83 Decreased By ▼ -0.17 (-2.13%)
PPL 151.60 Increased By ▲ 0.43 (0.28%)
PRL 26.59 Decreased By ▼ -0.29 (-1.08%)
PTC 16.06 Increased By ▲ 0.06 (0.38%)
SEARL 82.50 Increased By ▲ 4.30 (5.5%)
TELE 7.49 Increased By ▲ 0.10 (1.35%)
TOMCL 35.30 Decreased By ▼ -0.37 (-1.04%)
TPLP 8.23 Increased By ▲ 0.32 (4.05%)
TREET 16.19 Increased By ▲ 0.30 (1.89%)
TRG 52.75 Decreased By ▼ -0.01 (-0.02%)
UNITY 26.60 Increased By ▲ 0.05 (0.19%)
WTL 1.24 Decreased By ▼ -0.03 (-2.36%)
BR100 9,931 Increased By 10.4 (0.1%)
BR30 30,780 Increased By 28.7 (0.09%)
KSE100 93,531 Increased By 306.2 (0.33%)
KSE30 28,983 Increased By 98.4 (0.34%)

Pfizer Inc will pay $11.6 billion to buy migraine pill maker Biohaven Pharmaceutical, marking the biggest deal by the cash-rich drugmaker since 2016 to beef up its portfolio ahead of patent losses for some cancer drugs.

The deal, announced on Tuesday, will give Pfizer access to Biohaven’s approved rimegepant, a potential blockbuster that belong to a class of migraine treatments known as calcitonin gene-related peptide (CGRP) inhibitors.

Flush with about $32 billion in cash on hand after its success with COVID-19 drugs, Pfizer has been looking to add treatments as patents for its top-selling drugs like blood thinner Eliquis near expiration.

Pfizer Q1 revenues jump 77% to $25.7bn on Covid-19 vaccine

The company also expects sales of its COVID-19 vaccines to drop from last year’s highs.

“Investors will like this deal. Given Pfizer’s strong balance sheet, this is still a small acquisition and we would expect more such deals,” Wells Fargo analyst Mohit Bansal said in a note.

The Biohaven deal is its largest since Pfizer’s $14 billion purchase of cancer drugmaker Medivation in 2016.

Pfizer will acquire all Biohaven shares that it does not already own for $148.50 per share in cash, a 78.6% premium to last closing price. It had taken a 2.6% stake in Biohaven in November.

Biohaven shares jumped 70.1% to $141.39 before the bell, while Pfizer was trading flat at $48.60.

With this deal, Pfizer will compete in a crowded market for migraine treatments from other large drugmakers such as Eli Lilly.

Biohaven’s rimegepant, sold as Nurtec ODT in the United States, is approved for use as both a treatment and preventative for migraines and is expected to bring in sales of over $4 billion by 2030. It brought in sales of $462.5 million in 2021.

Biohaven is also developing another CGRP inhibitor and testing two non-CGRP drugs in late-stage studies.

After the deal closes, Biohaven shareholders, including Pfizer, will get 0.5 of a share of a new publicly traded company that will retain Biohaven’s non-CGRP treatments.

Comments

Comments are closed.